Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

Press release |
27 March 2003
Intellectual property and trade Research and development
European Union

The price of essential medicines in developing countries: The member states of the European Union must strengthen the European price regulation scheme

Press release |
13 February 2003
HIV/AIDS Intellectual property and trade

Bowing to pressure, Roche cuts its price for AIDS drug nelfinavir

Press release |
12 February 2003
Intellectual property and trade

Sell-out at WTO on Doha declaration?

Press release |
06 February 2003
Tropical & neglected diseases
Burkina Faso

New Meningitis Vaccine Welcomed — But Will It Need to be Rationed?

Press release |
30 January 2003
HIV/AIDS

MSF Welcomes President Bush’s Commitment to Scale-Up Access to Affordable AIDS Treatment, But Warns US Against Breaking Promises, Taking a Unilateral Approach

Press release |
24 January 2003
HIV/AIDS Intellectual property and trade

MSF Responds to Pharmacia's Announcement on Non-profit Distribution of AIDS Drug

Press release |
20 December 2002
Intellectual property and trade

Break in negotiations provides last opportunity to fix flaw in the TRIPS Agreement

Press release |
12 December 2002
HIV/AIDS
South Africa

Mandela joins MSF to scale up AIDS treatment in South Africa

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury